Top-Searched Lab Tests
Explore Conditions
Explore Biomarkers
Explore Diagnostic Labs
New Lab Tests
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| Guardant360 Tissue | NGS | Tissue | 10-14 d | Guardant Health |
| xT CDx | NGS | Tissue, Whole Blood, Saliva | 10-14 d | Tempus AI |
| Guardant360 CDx | NGS | Whole Blood | 7 d | Guardant Health |
| MI Cancer Seek® | NGS | Tumor Tissue, Tissue, Plasma | 14 d | Caris Life Sciences |
| Caris Assure | NGS | Whole Blood | — | Caris Life Sciences |
Guardant360 Tissue
Methodology:NGS
Specimen:Tissue
TAT:10-14 d
Lab:Guardant Health
xT CDx
Methodology:NGS
Specimen:Tissue, Whole Blood, Saliva
TAT:10-14 d
Lab:Tempus AI
Guardant360 CDx
Methodology:NGS
Specimen:Whole Blood
TAT:7 d
Lab:Guardant Health
MI Cancer Seek®
Methodology:NGS
Specimen:Tumor Tissue, Tissue, Plasma
TAT:14 d
Lab:Caris Life Sciences
Caris Assure
Methodology:NGS
Specimen:Whole Blood
TAT:—
Lab:Caris Life Sciences
Featured Companion Diagnostics
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| xT CDx | NGS | Tissue, Whole Blood, Saliva | 10-14 d | Tempus AI |
| Vysis Chronic Lymphocytic Leukemia (CLL) Panel | Chromosomal / Cytogenetics | Whole Blood, Bone Marrow | 5 d | MPLN |
| PMS2 Microsatellite Instability, technical only | Immunoassay | Tissue, Tissue, Tissue | 2 d | MPLN |
| PMS2 Microsatellite Instability | Immunoassay | Tissue, Tissue, Tissue | 2 d | MPLN |
| PD-L1 (SP263), technical only | Immunoassay | Tissue, Tissue, Tissue | 2 d | MPLN |
xT CDx
Methodology:NGS
Specimen:Tissue, Whole Blood, Saliva
TAT:10-14 d
Lab:Tempus AI
Vysis Chronic Lymphocytic Leukemia (CLL) Panel
Methodology:Chromosomal / Cytogenetics
Specimen:Whole Blood, Bone Marrow
TAT:5 d
Lab:MPLN
PMS2 Microsatellite Instability, technical only
Methodology:Immunoassay
Specimen:Tissue, Tissue, Tissue
TAT:2 d
Lab:MPLN
PMS2 Microsatellite Instability
Methodology:Immunoassay
Specimen:Tissue, Tissue, Tissue
TAT:2 d
Lab:MPLN
PD-L1 (SP263), technical only
Methodology:Immunoassay
Specimen:Tissue, Tissue, Tissue
TAT:2 d
Lab:MPLN
Featured Sponsored Testing
| Program Name | Therapeutic Area(s) | Condition | Lab |
|---|---|---|---|
| Alnylam Act® hATTR Amyloidosis | Metabolic | Acute Hepatic Porphyria (AHP) | Prevention Genetics |
| Alnylam Act® Acute Hepatic Porphyria | Cardiology, Neurology | Hereditary ATTR Amyloidosis | Prevention Genetics |
| Alnylam Act® Primary Hyperoxaluria Type 1 (45 genes) | Nephrology, Urology | Primary Hyperoxaluria Type 1 (PH1) | Prevention Genetics |
| Alnylam Act® Primary Hyperoxaluria Type 1 (3 genes) | Nephrology, Urology | Primary Hyperoxaluria Type 1 (PH1) | Prevention Genetics |
| ENPP1 and ABCC6 Sequencing | Cardiology, Metabolic | ENPP1 and ABCC6 Deficiencies | Prevention Genetics |
Alnylam Act® hATTR Amyloidosis
Therapeutic Area(s):Metabolic
Condition:Acute Hepatic Porphyria (AHP)
Lab:Prevention Genetics
Alnylam Act® Acute Hepatic Porphyria
Therapeutic Area(s):Cardiology, Neurology
Condition:Hereditary ATTR Amyloidosis
Lab:Prevention Genetics
Alnylam Act® Primary Hyperoxaluria Type 1 (45 genes)
Therapeutic Area(s):Nephrology, Urology
Condition:Primary Hyperoxaluria Type 1 (PH1)
Lab:Prevention Genetics
Alnylam Act® Primary Hyperoxaluria Type 1 (3 genes)
Therapeutic Area(s):Nephrology, Urology
Condition:Primary Hyperoxaluria Type 1 (PH1)
Lab:Prevention Genetics
ENPP1 and ABCC6 Sequencing
Therapeutic Area(s):Cardiology, Metabolic
Condition:ENPP1 and ABCC6 Deficiencies
Lab:Prevention Genetics